Ascentage Pharma (6855.HK) - May Not Survive "This Winter"

402 Views22 Nov 2022 09:04
Ascentage has proved its R&D capability, but R&D risk/cash shortage/commercialization challenges make it difficult for Ascentage to achieve break-even. Ascentage must first solve the survival problem.
SUMMARY
(Sign Up to Access)
Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:
  • Unlock research summaries
  • Follow top, independent analysts
  • Receive personalised alerts
  • Access Analytics, Events and more

Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.

Upgrade later to our paid plans for full-access.

or
Already have an account? Sign In Now
Full Insight
(Paid Plans Only, 4-minute read)
Discussions
(Paid Plans Only)
chart-bar
x